These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24506342)

  • 1. Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-naïve patients, in combination therapy and after treatment switch.
    Laux G; Huttner NA;
    Int J Psychiatry Clin Pract; 2014 Jun; 18(2):86-96. PubMed ID: 24506342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI.
    Laux G;
    Pharmacopsychiatry; 2012 Nov; 45(7):284-91. PubMed ID: 22592503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled Analysis of Four Non-Interventional Studies: Effectiveness and Tolerability of the Antidepressant Agomelatine in Daily Practice.
    Laux G; Barthel B; Hajak G; Lemke M; Volz HP
    Adv Ther; 2017 Apr; 34(4):895-914. PubMed ID: 28214983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S; Hamon M
    World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of depression and melatonergic antidepressant treatment alone and in combination with sedative-hypnotics on heart rate variability: Implications for cardiovascular risk.
    Chang CC; Tzeng NS; Yeh CB; Kuo TBJ; Huang SY; Chang HA
    World J Biol Psychiatry; 2018 Aug; 19(5):368-378. PubMed ID: 28281386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT
    Tchekalarova J; Kortenska L; Ivanova N; Atanasova M; Marinov P
    Psychopharmacology (Berl); 2020 Feb; 237(2):503-518. PubMed ID: 31720718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agomelatine for Depression in Parkinson Disease: Additional Effect on Sleep and Motor Dysfunction.
    Avila A; Cardona X; Martin-Baranera M; Leon L; Caballol N; Millet P; Bello J
    J Clin Psychopharmacol; 2015 Dec; 35(6):719-23. PubMed ID: 26444951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Agomelatine: the first "melatoninergic" antidepressant].
    Bánki MC
    Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Problems of depressive insomnia].
    Tarakanova EA; Ivanchuk ÉG; Rostovshchikov VV
    Vestn Ross Akad Med Nauk; 2014; (7-8):153-7. PubMed ID: 25563018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and co-morbid intellectual disability.
    Ballester P; Martínez MJ; Inda MD; Javaloyes A; Richdale AL; Muriel J; Belda C; Toral N; Morales D; Fernández E; Peiró AM
    J Psychopharmacol; 2019 Nov; 33(11):1395-1406. PubMed ID: 31423939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
    Lemoine P; Guilleminault C; Alvarez E
    J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agomelatine as chronopsychopharmaceutics restoring circadian rhythms and enhancing resilience to stress: a wishfull thinking or an innovative strategy for superior management of depression?
    Jakovljević M
    Psychiatr Danub; 2011 Mar; 23(1):2-9. PubMed ID: 21448091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical experiences with agomelatine. The inner ear has to be synchronized again].
    MMW Fortschr Med; 2010 Mar; 152(10):46-7. PubMed ID: 20380235
    [No Abstract]   [Full Text] [Related]  

  • 15. Agomelatine in the treatment of seasonal affective disorder.
    Pjrek E; Winkler D; Konstantinidis A; Willeit M; Praschak-Rieder N; Kasper S
    Psychopharmacology (Berl); 2007 Mar; 190(4):575-9. PubMed ID: 17171557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focus on agomelatine.
    Green B
    Curr Med Res Opin; 2011 Apr; 27(4):745-9. PubMed ID: 21271795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major depressive disorder, anhedonia and agomelatine: an open-label study.
    Di Giannantonio M; Di Iorio G; Guglielmo R; De Berardis D; Conti CM; Acciavatti T; Cornelio M; Martinotti G
    J Biol Regul Homeost Agents; 2011; 25(1):109-14. PubMed ID: 21382280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.
    Descamps A; Rousset C; Millan MJ; Spedding M; Delagrange P; Cespuglio R
    Psychopharmacology (Berl); 2009 Jul; 205(1):93-106. PubMed ID: 19370342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agomelatine: a preliminary review of a new antidepressant.
    Zupancic M; Guilleminault C
    CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Could agomelatine be the ideal antidepressant?
    Pandi-Perumal SR; Srinivasan V; Cardinali DP; Monti MJ
    Expert Rev Neurother; 2006 Nov; 6(11):1595-608. PubMed ID: 17144776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.